<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04216511</url>
  </required_header>
  <id_info>
    <org_study_id>CAALC-007-EarlyCDT Lung China</org_study_id>
    <nct_id>NCT04216511</nct_id>
  </id_info>
  <brief_title>Early Cancer Detection Test - Lung Cancer China</brief_title>
  <acronym>ECLC</acronym>
  <official_title>Clinic Validation of Autoantibody Panel for Lung Cancer Diagnosis in Chinese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bai Chunxue</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gene Tech (Shanghai) Company Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Alliance Against Lung Cancer</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung cancer is the most common cancer in China from both incidence and mortality rate point
      of view, with significantly lower 5-year survival rate than average. Early detection is the
      recognized solution. LDCT is more and more popular accepted as an effective screening
      methodology but leads to numerous indeterminate pulmonary nodules for physicians to
      distinguish too. The value of autoantibody test in risk assessing of IPNs as well as early
      detection of lung cancer in high risk population has been demonstrated in clinical practice
      and trial but mainly in Caucasian. Purpose of this study is to understand the sensitivity,
      specificity and accuracy of candidate autoantibodies, and consequently explore the
      autoantibody combination with best clinical performance in Chinese population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Autoantibody panel with best clinical performance in Chinese population</measure>
    <time_frame>Oct.30, 2020</time_frame>
    <description>The combination which can achieve best sensitivity at 90% specificity, and its sensitivity, accuracy and PPV.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Case-Lung Cancer</arm_group_label>
    <description>Patients with definite lung cancer diagnosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Either patients with benign pulmonary nodule, or healthy individuals without pulmonary nodule but with risk factors to develop lung cancer matched to lung cancer group</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Tumor autoantibody detection</intervention_name>
    <description>Level of a set of autoantibodies potentially relative with lung cancer will be tested for each of the participants.</description>
    <arm_group_label>Case-Lung Cancer</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum or plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals diagnosed with lung cancer, benign pulmonary nodule or identified as at-risk
        healthy volunteer in participating hospitals of this study, from the recruitment starting
        date, till the end of the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 18 or above.

          -  Individuals complying with either of the following

               1. diagnosed as lung cancer (histopathologically confirmed);

               2. diagnosed as benign pulmonary nodule (confirmed by pathology or by follow-up
                  based on 2018 Chinese Consensus on Pulmonary Nodule Diagnosis and Treatment);

               3. without pulmonary nodule but with lung cancer risk factor, age &amp; gender matched
                  recruited lung cancer patients.

          -  Participant is willing and able to provide necessary information required in CRF.

          -  Participant is willing and able to give informed consent for participation in the
             study.

        Exclusion Criteria:

          -  History of any cancer;

          -  Lung cancer patient who received or is receiving any treatment, including but not
             limited to surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunxue Bai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunxue Bai, MD</last_name>
    <phone>18621170011</phone>
    <email>bai.chunxue@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jian Zhou, MD</last_name>
    <phone>18221223320</phone>
    <email>zhou.jian@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunxue Bai, MD</last_name>
      <phone>18621170011</phone>
      <email>bai.chunxue@zs-hospital.sh.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jian Zhou, MD</last_name>
      <phone>18221223320</phone>
      <email>zhou.jian@fudan.edu.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiayuan Sun, MD</last_name>
      <phone>86-21-22200000</phone>
      <phone_ext>1511</phone_ext>
      <email>jysun1976@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Province People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaoju Zhang</last_name>
      <email>zhangxiaoju1010@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 31, 2019</study_first_submitted>
  <study_first_submitted_qc>December 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>December 31, 2019</last_update_submitted>
  <last_update_submitted_qc>December 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Alliance Against Lung Cancer</investigator_affiliation>
    <investigator_full_name>Bai Chunxue</investigator_full_name>
    <investigator_title>Chairman</investigator_title>
  </responsible_party>
  <keyword>Tumor Autoantibody</keyword>
  <keyword>Early Detection</keyword>
  <keyword>Indeterminate Pulmonary Nodule</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoantibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

